Trial
NCT05953831
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Cardior Pharmaceuticals GmbH
Collaborators
—
Condition
Heart Failure With Preserved Ejection Fraction
Intervention
CDR132L
Why stopped
Transfer of study responsibility and planning
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-09